JP2006505277A5 - - Google Patents

Info

Publication number

JP2006505277A5

JP2006505277A5 JP2004551530A JP2004551530A JP2006505277A5 JP 2006505277 A5 JP2006505277 A5 JP 2006505277A5 JP 2004551530 A JP2004551530 A JP 2004551530A JP 2004551530 A JP2004551530 A JP 2004551530A JP 2006505277 A5 JP2006505277 A5 JP 2006505277A5

Authority

JP

Japan

Prior art keywords

antibody

seq

epitope

binding fragment

variable region

Prior art date

2003-11-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 claims description 42
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 14
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 14
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 229940079593 drug Drugs 0.000 claims description 4
• 239000003814 drug Substances 0.000 claims description 4
• 239000012634 fragment Substances 0.000 claims 35
• 238000000034 method Methods 0.000 claims 10
• 239000012620 biological material Substances 0.000 claims 5
• 239000008194 pharmaceutical composition Substances 0.000 claims 5
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
• 239000003153 chemical reaction reagent Substances 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 108091033319 polynucleotide Proteins 0.000 claims 3
• 239000002157 polynucleotide Substances 0.000 claims 3
• 102000040430 polynucleotide Human genes 0.000 claims 3
• 229940002612 prodrug Drugs 0.000 claims 3
• 239000000651 prodrug Substances 0.000 claims 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
• 238000007792 addition Methods 0.000 claims 2
• 239000012472 biological sample Substances 0.000 claims 2
• 230000037430 deletion Effects 0.000 claims 2
• 238000012217 deletion Methods 0.000 claims 2
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 2
• 230000037431 insertion Effects 0.000 claims 2
• 238000003780 insertion Methods 0.000 claims 2
• 230000035772 mutation Effects 0.000 claims 2
• 239000002773 nucleotide Substances 0.000 claims 2
• 125000003729 nucleotide group Chemical group 0.000 claims 2
• UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 108090000790 Enzymes Proteins 0.000 claims 1
• 241000588724 Escherichia coli Species 0.000 claims 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
• 206010024291 Leukaemias acute myeloid Diseases 0.000 claims 1
• 108091034117 Oligonucleotide Proteins 0.000 claims 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
• 229960002685 biotin Drugs 0.000 claims 1
• 235000020958 biotin Nutrition 0.000 claims 1
• 239000011616 biotin Substances 0.000 claims 1
• 229930195731 calicheamicin Natural products 0.000 claims 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 238000012219 cassette mutagenesis Methods 0.000 claims 1
• 230000010261 cell growth Effects 0.000 claims 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
• 229960004630 chlorambucil Drugs 0.000 claims 1
• 239000002872 contrast media Substances 0.000 claims 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
• 229960000975 daunorubicin Drugs 0.000 claims 1
• 229930188854 dolastatin Natural products 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 claims 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
• 229960001924 melphalan Drugs 0.000 claims 1
• 229910021645 metal ion Inorganic materials 0.000 claims 1
• 229960000485 methotrexate Drugs 0.000 claims 1
• 229960004857 mitomycin Drugs 0.000 claims 1
• 230000002285 radioactive effect Effects 0.000 claims 1
• 239000000523 sample Substances 0.000 claims 1
• 238000012216 screening Methods 0.000 claims 1
• 238000002741 site-directed mutagenesis Methods 0.000 claims 1
• 229960003048 vinblastine Drugs 0.000 claims 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
• 229960004528 vincristine Drugs 0.000 claims 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
• 241001529936 Murinae Species 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 239000002299 complementary DNA Substances 0.000 description 5
• 238000011579 SCID mouse model Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 238000011255 standard chemotherapy Methods 0.000 description 2
• 238000004885 tandem mass spectrometry Methods 0.000 description 2
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 1
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 1
• 229930126263 Maytansine Natural products 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1